Carboplatin Injection Shortage: Supply Updates and Manufacturer Availability
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Carboplatin Injection, a critical oncology medication, is currently facing supply challenges with several manufacturers reporting limited availability, backorders, or discontinuations.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Carboplatin) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Carboplatin Injection (brand name: CARBOPLATIN) is currently listed as being in shortage. This medication is classified under the oncology therapeutic category and is provided in an injection dosage form. The shortage status is currently active, having been first posted on April 28, 2023, and most recently updated on February 2, 2026.
Which Manufacturers Are Affected
Several manufacturers are reporting varying levels of availability for Carboplatin Injection:
- Teva Pharmaceuticals USA, Inc. (800-545-8800):
- Limited Availability: 10 mg/1 mL (NDC 0703-4239-01) with an estimated recovery date of June 2026.
- Available: Multiple presentations (NDC 0703-4244-01, 0703-4246-01, 0703-4248-01).
- Accord Healthcare Inc. (866-941-7875, option 2):
- Unavailable: Multiple presentations (NDC 16729-295-12, 16729-295-34).
- Discontinued: The manufacture of certain presentations has been discontinued (NDC 16729-295-31, 16729-295-33).
- Eugia US LLC (888-238-7880):
- Unavailable: 450 mg/45 mL (NDC 55150-335-01) is on backorder with recovery TBD. Patients and providers are advised to check wholesalers for inventory.
- Available: 600 mg/60 mL (NDC 55150-386-01).
- Fresenius Kabi USA, LLC (888-386-1300):
- Available: 10 mg/1 mL (NDC 63323-172-60). Providers should check wholesalers for current inventory.
Why There's a Shortage
The reason for the shortage of Carboplatin Injection is officially listed as "Other." No further specific details regarding the cause of the supply disruption were provided in the official report.
What Patients Should Do
Patients who rely on Carboplatin for their treatment should be aware that while some presentations are available, others are currently difficult to source.
- Consult Your Healthcare Provider: It is essential to speak with your oncologist or healthcare team regarding your treatment plan and how this shortage may affect your care.
- Speak with Your Pharmacist: Pharmacists may have the most up-to-date information on local inventory and wholesaler availability.
- Contact Manufacturers: If you have specific questions about a particular presentation, you may use the contact information provided above.
Disclaimer: This article is for informational purposes only. Patients should always consult with their healthcare provider or pharmacist for medical advice and treatment options.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category